Targeting tumor-associated macrophages and inhibition of MCP-1 reduce angiogenesis and tumor growth in a human melanoma xenograft - PubMed (original) (raw)
. 2007 Aug;127(8):2031-41.
doi: 10.1038/sj.jid.5700827. Epub 2007 Apr 26.
Affiliations
- PMID: 17460736
- DOI: 10.1038/sj.jid.5700827
Free article
Targeting tumor-associated macrophages and inhibition of MCP-1 reduce angiogenesis and tumor growth in a human melanoma xenograft
Silvina Gazzaniga et al. J Invest Dermatol. 2007 Aug.
Free article
Abstract
Chemokines such as monocyte chemoattractant protein (MCP)-1 are key agonists that attract macrophages to tumors. In melanoma, it has been previously shown that variable levels of MCP-1/CCL2 appear to correlate with infiltrating macrophages and tumor fate, with low to intermediate levels of the chemokine contributing to melanoma development. To work under such conditions, a poorly tumorigenic human melanoma cell line was transfected with an expression vector encoding MCP-1. We found that M2 macrophages are associated to MCP-1+ tumors, triggering a profuse vascular network. To target the protumoral macrophages recruitment and reverting tumor growth promotion, clodronate-laden liposomes (Clod-Lip) or bindarit were administered to melanoma-bearing mice. Macrophage depletion after Clod-Lip treatment induced development of smaller tumors than in untreated mice. Immunohistochemical analysis with an anti-CD31 antibody revealed scarce vascular structures mainly characterized by narrow vascular lights. Pharmacological inhibition of MCP-1 with bindarit also reduced tumor growth and macrophage recruitment, rendering necrotic tumor masses. We suggest that bindarit or Clod-Lip abrogates protumoral-associated macrophages in human melanoma xenografts and could be considered as complementary approaches to antiangiogenic therapy.
Similar articles
- Monocyte chemoattractant protein-1 transfection induces angiogenesis and tumorigenesis of gastric carcinoma in nude mice via macrophage recruitment.
Kuroda T, Kitadai Y, Tanaka S, Yang X, Mukaida N, Yoshihara M, Chayama K. Kuroda T, et al. Clin Cancer Res. 2005 Nov 1;11(21):7629-36. doi: 10.1158/1078-0432.CCR-05-0798. Clin Cancer Res. 2005. PMID: 16278381 - Macrophage depletion reduces monocyte chemotactic protein-1 and transforming growth factor-beta1 in healing rat vein grafts.
Wolff RA, Tomas JJ, Hullett DA, Stark VE, van Rooijen N, Hoch JR. Wolff RA, et al. J Vasc Surg. 2004 Apr;39(4):878-88. doi: 10.1016/j.jvs.2003.11.039. J Vasc Surg. 2004. PMID: 15071458 - Effects of MCP-1 inhibition by bindarit therapy in a rat model of polycystic kidney disease.
Zoja C, Corna D, Locatelli M, Rottoli D, Pezzotta A, Morigi M, Zanchi C, Buelli S, Guglielmotti A, Perico N, Remuzzi A, Remuzzi G. Zoja C, et al. Nephron. 2015;129(1):52-61. doi: 10.1159/000369149. Epub 2014 Dec 17. Nephron. 2015. PMID: 25531096 - Effects of the MCP-1 synthesis inhibitor bindarit on tumorigenesis and inflammatory markers in the C3(1)/SV40Tag mouse model of breast cancer.
Steiner JL, Davis JM, McClellan JL, Guglielmotti A, Murphy EA. Steiner JL, et al. Cytokine. 2014 Mar;66(1):60-8. doi: 10.1016/j.cyto.2013.12.011. Epub 2014 Jan 20. Cytokine. 2014. PMID: 24548426 Free PMC article. - Pro-tumor activities of macrophages in the progression of melanoma.
Wang H, Yang L, Wang D, Zhang Q, Zhang L. Wang H, et al. Hum Vaccin Immunother. 2017 Jul 3;13(7):1556-1562. doi: 10.1080/21645515.2017.1312043. Epub 2017 Apr 25. Hum Vaccin Immunother. 2017. PMID: 28441072 Free PMC article. Review.
Cited by
- Reprogramming Immune Cells for Enhanced Cancer Immunotherapy: Targets and Strategies.
Dong Y, Wan Z, Gao X, Yang G, Liu L. Dong Y, et al. Front Immunol. 2021 Apr 21;12:609762. doi: 10.3389/fimmu.2021.609762. eCollection 2021. Front Immunol. 2021. PMID: 33968014 Free PMC article. Review. - Macrophage polarization in pathology.
Sica A, Erreni M, Allavena P, Porta C. Sica A, et al. Cell Mol Life Sci. 2015 Nov;72(21):4111-26. doi: 10.1007/s00018-015-1995-y. Epub 2015 Jul 26. Cell Mol Life Sci. 2015. PMID: 26210152 Free PMC article. Review. - Plasmacytoid dendritic cells lead the charge against tumors.
Jiménez-Baranda S, Silva IP, Bhardwaj N. Jiménez-Baranda S, et al. J Clin Invest. 2012 Feb;122(2):481-4. doi: 10.1172/JCI61345. Epub 2012 Jan 17. J Clin Invest. 2012. PMID: 22251700 Free PMC article. - Therapeutic Potential of Natural Resources Against Endometriosis: Current Advances and Future Perspectives.
Gu X, Zhou H, Miao M, Hu D, Wang X, Zhou J, Teichmann AT, Yang Y, Wang C. Gu X, et al. Drug Des Devel Ther. 2024 Aug 21;18:3667-3696. doi: 10.2147/DDDT.S464910. eCollection 2024. Drug Des Devel Ther. 2024. PMID: 39188919 Free PMC article. Review. - Type I interferons inhibit the generation of tumor-associated macrophages.
U'Ren L, Guth A, Kamstock D, Dow S. U'Ren L, et al. Cancer Immunol Immunother. 2010 Apr;59(4):587-98. doi: 10.1007/s00262-009-0776-6. Epub 2009 Oct 14. Cancer Immunol Immunother. 2010. PMID: 19826812 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous